Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: HIV Infections
Interventions: Treatment regimen change; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 23
States / cities: Menlo Park, California • Stanford, California • Torrance, California + 15 more

Conditions: Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions: Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, Hypertension Complicated
Interventions: RBPM, MII; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts

Conditions: Aging
Interventions: Tai Chi intervention, Usual care condiition; Device · Other
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 60 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Advanced Cancers
Interventions: Placebo, Glutamine, Questionnaires; Other · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 17 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Interventions: Entinostat, Placebo, Erlotinib; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 30
States / cities: Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more

Conditions: Acute Otitis Media
Interventions: AR01, Placebo Comparator; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 102
States / cities: Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more

Conditions: Graves Disease, Hashimoto Disease
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Remote monitoring; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Psilocybin
Interventions: Psilocybin, Midazolam, Saline; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Thrombotic Microangiopathy
Interventions: Ravulizumab, Placebo, Best Supportive Care; Biological · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Tucson, Arizona • Orange, California • Washington D.C., District of Columbia + 14 more

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more

Conditions: Alzheimer's Disease
Interventions: CHF 5074 1x, CHF 5074 2x, CHF 5074 3x; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more

Conditions: Epilepsy
Interventions: Placebo, Rufinamide; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 77
States / cities: Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more

Conditions: Giant Cell Arteritis
Interventions: Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more

Conditions: Traumatic Brain Injury
Interventions: aerobic exercise, stretching/toning; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 34
States / cities: Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more

Conditions: Mucositis, Pain, Leukemia
Interventions: Real Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Honolulu, Hawaii • Boise, Idaho • Voorhees Township, New Jersey + 3 more

Conditions: Head and Neck Cancer, Pain, Postoperative
Interventions: Stellate ganglion block; Procedure
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Rosacea
Interventions: Burt's Bees Skin Care Regimen, Control Regimen; Other
Lead sponsor: Burt's Bees Inc.; Industry
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: High Point, North Carolina

Search by objective public record fields.

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

Feasibility and Efficacy of A Remote Tai Chi Program in Older Adults

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Preoperative Corticosteroids in Autoimmune Thyroid Disease

A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy

The RECAP2 Study: Midazolam and Psilocybin

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

The Effect of Aerobic Exercise on Mild Traumatic Brain Injury

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Acupuncture for Mucositis Pain in Cancer Care

Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy

Stellate Ganglion Block in Head and Neck Cancer Surgery

The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea